Pseudomyxoma Peritonei

A condition characterized by poorly-circumscribed gelatinous masses filled with malignant mucin-secreting cells. Forty-five percent of pseudomyxomas arise from the ovary, usually in a mucinous cystadenocarcinoma (CYSTADENOCARCINOMA, MUCINOUS), which has prognostic significance. Pseudomyxoma peritonei must be differentiated from mucinous spillage into the peritoneum by a benign mucocele of the appendix. (Segen, Dictionary of Modern Medicine, 1992)

Also Known As:

Networked: 267 relevant articles (21 outcomes, 17 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Ascites
2.	Neoplasms (Cancer)
3.	Appendiceal Neoplasms (Appendix Cancer)
4.	Peritoneal Diseases
5.	Carcinoma (Carcinomatosis)

Experts

1.	Morris, David L: 17 articles (10/2015 - 04/2009)
2.	Chua, Terence C: 15 articles (01/2014 - 04/2009)
3.	Liauw, Winston: 9 articles (10/2015 - 10/2010)
4.	Sugarbaker, Paul H: 9 articles (08/2015 - 04/2004)
5.	Sugarbaker, P H: 9 articles (12/2014 - 05/2000)
6.	Deraco, Marcello: 8 articles (07/2013 - 09/2002)
7.	Yan, Tristan D: 8 articles (07/2012 - 02/2007)
8.	Kusamura, Shigeki: 7 articles (07/2013 - 09/2002)
9.	Baratti, Dario: 7 articles (07/2013 - 04/2004)
10.	Zhao, Jing: 7 articles (06/2013 - 07/2009)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Pseudomyxoma Peritonei:

1.	MucinsIBA 09/01/2002 - "Our study specifically investigated MUC2 and MUC5AC because these two mucins possessed the physicochemical property of being gel-forming, a property exhibited by pseudomyxoma peritonei grossly. " 11/01/2015 - "Spillage of mucin into peritoneal cavity may otherwise lead to pseudomyxoma peritonei. " 10/20/2015 - "This capability supports the use of this combination formulation in locoregional approaches for reducing the adverse effects of the aberrantly secreted gel-forming mucins, as in pseudomyxoma peritonei and similar pathologies with ectopic production of mucin. " 02/14/2014 - "Pseudomyxoma peritonei is a condition characterised by dissemination of mucin-producing neoplastic cells throughout the peritoneal cavity. " 02/01/2014 - "Each year, about two per million individuals will be diagnosed with pseudomyxoma peritonei, a disease characterised by the intra-abdominal growth of neoplastic mucin-secreting cells on peritoneal surfaces. "
2.	Cisplatin (Platino)FDA LinkGeneric 11/01/2007 - "We examined five cases of pseudomyxoma peritonei with treatments of cytoreduction surgery, abdominal lavage and intraperiotoneal administration of cisplatin (CDDP). " 07/01/1998 - "[Three cases of Pseudomyxoma peritonei treated with intraperitoneal inoculation of cisplatin through an implantable port system]." 12/01/1995 - "Successful pregnancy in a patient with pseudomyxoma peritonei arising from ovarian mucinous cystadenocarcinoma treated with cisplatin." 10/20/1989 - "We confirm the treatment of the intraperitoneal inoculation of cisplatin after dextrose washing with the cytoreductive surgery is one of the most effective therapies for pseudomyxoma peritonei." 12/01/2014 - "•This is the first report of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a woman with pseudomyxoma peritonei.•PIPAC achieved clinical and histological disease remission.•PIPAC with cisplatin and doxorubicin may be effective in pseudomyxoma peritonei. "
3.	Fluorouracil (Carac)FDA LinkGeneric 10/01/1999 - "Given the results above, intraperitoneal administrations of this combined CDDP, 5-FU, MMC therapy may be effective for patients with pseudomyxoma peritonei." 01/01/1993 - "Intraperitoneal 5-FU appears to be effective in pseudomyxoma peritonei. " 10/01/1999 - "Herein, we report five cases of pseudomyxoma peritonei that responded to a combined postsurgical therapy consisting of CDDP, 5-FU and MMC. " 10/01/1999 - "[Intraperitoneal administration of a combined CDDP, 5-FU and MMC therapy for pseudomyxoma peritonei]." 09/01/1996 - "Herein, we report two cases of pseudomyxoma peritonei that responded to a combined postsurgical therapy consisting of CDDP, 5-FU and MMC. "
4.	Doxorubicin (Adriamycin)FDA LinkGeneric 12/01/2014 - "•This is the first report of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a woman with pseudomyxoma peritonei.•PIPAC achieved clinical and histological disease remission.•PIPAC with cisplatin and doxorubicin may be effective in pseudomyxoma peritonei. " 12/01/2014 - "Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in a woman with pseudomyxoma peritonei: A case report." 10/01/2015 - "First evidence in humans with peritoneal cancer from ovarian cancer, gastric cancer, colon cancer, appendiceal cancer, and pseudomyxoma peritonei has been obtained suggesting clinical antitumor activity and procedural safety of repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin. " 10/01/1985 - "This is the first case of pseudomyxoma peritonei secondary to an ovarian primary possibly cured by systemic cis-platinum, doxorubicin, and cyclophosphamide." 10/01/1985 - "Successful treatment of pseudomyxoma peritonei of ovarian origin with cis-platinum, doxorubicin, and cyclophosphamide."
5.	Glucose (Dextrose)FDA LinkGeneric 11/01/1993 - "A case of pseudomyxoma peritonei treated successfully with intraabdominal infusion of a 2.5% solution of dextrose is reported." 03/01/1995 - "To test the mucolytic effect of 5% and 10% dextrose-water solutions and to determine what could be a true mucolytic agent, in vitro and in vivo studies were undertaken in two proven pseudomyxoma peritonei cases. " 08/01/1993 - "A patient with malignant pseudomyxoma peritonei underwent a palliative surgical resection and intraperitoneal lavage with 5% dextrose. " 08/01/1981 - "Two patients with pseudomyxoma peritonei (PP) had repeated intraperitoneal washing with 5% dextrose in water. " 08/01/2007 - "[Transient hyperglycemia following intra-peritoneal irrigation with 5% glucose in a patient with pseudomyxoma peritonei]."
6.	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 05/15/2012 - "This study examines the potential efficacy of hydrogen peroxide and ascorbic acid in the dissolution of mucinous ascites from pseudomyxoma peritonei. " 05/15/2012 - "The mucolytic property of the final mixture (0.2% ascorbic acid/0.2% hydrogen peroxide) was pH-dependent and showed maximal degradation at pH 4.5 and declined as it reached towards neutral pH. The current study introduces the potential applicability of a formulation that holds promise as a mucolytic agent in patients with mucinous ascites from pseudomyxoma peritonei." 05/15/2012 - "Mucolysis by ascorbic acid and hydrogen peroxide on compact mucin secreted in pseudomyxoma peritonei."
7.	Ascorbic Acid (Vitamin C)FDA LinkGeneric 05/15/2012 - "This study examines the potential efficacy of hydrogen peroxide and ascorbic acid in the dissolution of mucinous ascites from pseudomyxoma peritonei. " 05/15/2012 - "The mucolytic property of the final mixture (0.2% ascorbic acid/0.2% hydrogen peroxide) was pH-dependent and showed maximal degradation at pH 4.5 and declined as it reached towards neutral pH. The current study introduces the potential applicability of a formulation that holds promise as a mucolytic agent in patients with mucinous ascites from pseudomyxoma peritonei." 05/15/2012 - "Mucolysis by ascorbic acid and hydrogen peroxide on compact mucin secreted in pseudomyxoma peritonei."
8.	AntigensIBA 03/01/1999 - "Herein, we report 3 patients with pseudomyxoma peritonei with high serum carbohydrate antigen 19-9 (CA19-9) levels. " 06/01/2013 - "Carbohydrate antigen 19-9 (CA 19-9) is an independent prognostic indicator in pseudomyxoma peritonei post cytoreductive surgery and perioperative intraperitoneal chemotherapy." 12/01/2002 - "We studied the prognostic value of baseline and serial carcinoembryonic antigen (CEA) and carbohydrate antigen 19.9 (CA19.9) measurements in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). " 12/01/2002 - "Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy." 11/01/2007 - "Seven cycles of mFOLFOX6 treatment resulted in a marked decrease in ascites and serum levels of carcinoembryonic antigen and carbohydrate antigen 19-9. At laparotomy, a diagnosis of pseudomyxoma peritonei caused by cancer of the appendix was made. "
9.	Dextrans (Dextran)FDA Link 06/15/1992 - "A role for dextran in pseudomyxoma peritonei?" 11/01/1989 - "The result of treatment by washing with dextran was thought to be an effective therapy for pseudomyxoma peritonei." 10/20/1989 - "[Analysis of the treatment of pseudomyxoma peritonei--cytoreductive surgery with chemotherapy and intraperitoneal inoculation after washing with dextran]." 10/20/1989 - "Twelve cases of pseudomyxoma peritonei in the Department of Obstetrics and Gynecology in Kurume University School of Medicine were categorized in three groups by treatment; 3 cases with just operations, 6 cases with chemotherapies after operations and 3 cases with chemotherapies and intraperitoneal inoculations of cisplatin after washing with dextran. " 08/01/2001 - "[A case of pseudomyxoma peritonei treated successfully with intraperitoneal administration of CBDCA and etoposide, followed by local delivery of dextran with CDDP during surgery]."
10.	Carcinoembryonic AntigenIBA 06/01/2013 - "Preoperative carcinoembryonic antigen level predicts prognosis in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy." 12/01/2002 - "We studied the prognostic value of baseline and serial carcinoembryonic antigen (CEA) and carbohydrate antigen 19.9 (CA19.9) measurements in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). " 12/01/2002 - "Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy." 11/01/2007 - "Seven cycles of mFOLFOX6 treatment resulted in a marked decrease in ascites and serum levels of carcinoembryonic antigen and carbohydrate antigen 19-9. At laparotomy, a diagnosis of pseudomyxoma peritonei caused by cancer of the appendix was made. " 07/01/1988 - "Both cell lines have the following unique properties: (a) growth in vitro as delicate branching three-dimensional tumor particles within a wide gel of insoluble, often translucent mucus (proteoglycan); (b) production of large quantities of carcinoembryonic antigen; (c) ability to survive or adapt to growth in media free of serum, hormones, growth factors, and all protein; and (d) tumorigenicity in multiple sites in nude mice, including liver, with especially rapid growth in the peritoneal cavity as gelatinous material that is nonadherent and noninvasive and thus resembles pseudomyxoma peritonei. "

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 01/01/1996 - "The best outcome was achieved with pseudomyxoma peritonei of appendiceal origin with a time interval between surgeries of 2 or more years, a complete cytoreduction, and treatment with intraperitoneal chemotherapy. " 10/01/1994 - "Aggressive surgical therapy with-chemotherapy is effective in providing long-term relief or cure in pseudomyxoma peritonei." 09/01/2007 - "How safe and effective is surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei?" 02/01/2007 - "The efficacy of cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) for patients with pseudomyxoma peritonei (PMP) remains to be established. " 07/01/2013 - "Improved survival of patients with pseudomyxoma peritonei receiving intraperitoneal chemotherapy with cytoreductive surgery: a systematic review and meta-analysis."
2.	Laparotomy 01/01/2012 - "The syndrome pseudomyxoma peritonei is rare, present in only 2/10,000 laparotomies. " 01/01/2008 - "He underwent laparotomy under the impression of pseudomyxoma peritonei. " 08/01/2007 - "A 58-year-old man with a 1 year history of progressive abdominal distension underwent a laparotomy for pseudomyxoma peritonei. " 01/01/2007 - "In total, 123 patients (52 males; 41 percent) underwent laparotomy for a perforated appendiceal malignancy presenting as pseudomyxoma peritonei. " 05/01/2005 - "Laparotomy is the main tool for diagnosing pseudomyxoma peritonei. "
3.	Catheters 01/01/2014 - "Efficacy of a novel mucolytic agent on pseudomyxoma peritonei mucin, with potential for treatment through peritoneal catheters." 01/01/2014 - "Compared to current treatment for pseudomyxoma peritonei (PMP), the extraction of solubilised mucin through peritoneal catheter can be minimally invasive. "
4.	Appendectomy 11/01/2007 - "We report a case of a pseudomyxoma peritonei arising in an elderly patient with a previous medical history of appendectomy undergone in infancy. " 01/01/2007 - "Pseudomyxoma peritonei occurring after an uneventful 23 years interval from appendectomy." 04/01/2005 - "The authors present the case of a very rare pseudomyxoma peritonei as a late complication of appendectomy. " 10/01/1999 - "A 59-year-old women had a complete response who underwent an appendectomy, a right ovariectomy, and an omentectomy due to pseudomyxoma peritonei, and was postoperatively given a 50 mg intraperitoneal administration of CDDP. " 09/01/1996 - "Case 2 concerns a 59-year-old woman who underwent an appendectomy, a right ovariectomy, and an omentectomy due to pseudomyxoma peritonei, and was postoperatively given 50 mg intraperitoneal administration of CDDP. "
5.	Palliative Care (Palliative Medicine) 11/01/2003 - "A case of pseudomyxoma peritonei with a unique palliative therapy." 02/01/2014 - "Whole abdominopelvic radiotherapy in the palliative treatment of pseudomyxoma peritonei." 05/01/1983 - "These results: a) confirm the possibility of observing spreading distant metastasis in the pseudomyxoma peritonei; b) underline the potential interest of electron microscopic study in case of wavering diagnosis; c) show that the mucoid substance belongs to the group of neutral sulfomucins; d) legitimate, in the future, a trial of palliative treatment by neuraminidase in such cases."